Company profile / APLLTD

Alembic Pharmaceuticals

Other · 2 quarters tracked · source-linked performance and management context.

Research layer active

WatchCredibility 0/100Latest record q4-fy26

Latest revenue

₹1,848 Cr

verified financial record

Quarters tracked

source records in the directory

Delivery assessment

Across 3 tracked commitments: 0 delivered, 3 missed.

Call date

2026-05-15

latest available source date

Signal trajectory

2 actual quarters

Revenue (₹ Cr)PositiveWatchNegative

2 actual records

Values are taken from the available verified source records; sentiment color is a separate source-read indicator.

Current read

0/100

Across 3 tracked commitments: 0 delivered, 3 missed.

Latest source read

What changed this quarter?

Open quarter read

Alembic Pharmaceuticals reported Q4 FY26 revenue of ₹1,848 crore, up 4% YoY, with core EBITDA margin before R&D at 25% (vs 24% YoY). PAT of ₹203 crore included exceptional items and tax adjustments. India business grew 4% YoY, US showed volume-led growth, and API grew modestly. Management guided for low double-digit consolidated revenue growth in FY27, with R&D spend of ₹750-800 crore and capex of ₹300-350 crore. The US branded business (Pivya launch) is expected to be a near-term margin drag of 100-150 bps, offset by core operating leverage. Risks include sustained pricing pressure in generics, delayed ramp-up of new facilities, and execution risk in the branded specialty pivot.

Colored figures compare against the previous available record. Hover or focus one for the comparison.

Signal

Watch

Revenue

₹1,848 Cr

Source date

2026-05-15

Across the record

Quarter history.

2 source records

History modules

Follow the numbers and themes.

Revenue history PAT history Margin trend Guidance tracker Bear-case history Language trends FY26 summary